68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG.
Brad Kline, Surekha Yadav, Youngho Seo...
https://pubmed.ncbi.nlm.nih.gov/38697672/Actively Recruiting
Led by Thomas Hope · Updated on 2026-06-04
191
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating a new imaging method using radiolabeled agents called FAP-2286 to detect metastatic cancer in adults with solid tumors. FAP-2286 binds to a protein found on cancer-associated fibroblasts, present in various solid tumors such as breast, pancreas, sarcoma, prostate, bladder, colon, and head and neck cancers. This phase 1, multi-arm trial aims to assess the safety, dosimetry, uptake, and ability of FAP-2286 to detect metastatic disease and tumor uptake in these cancers. Participants receive either gallium-68 labeled 68Ga- or copper-64 labeled 64Cu- FAP-2286 injected intravenously before undergoing PET imaging. Imaging times vary by cohort and tracer type, ranging from 30 minutes to 24 hours after injection. Some participants may receive contrast during scans if clinically indicated. The study includes cohorts with and without metastatic disease and involves repeated imaging after treatment to evaluate changes in uptake. During the study, participants undergo PET scans lasting about 30 to 45 minutes at scheduled intervals depending on the tracer and disease status. Researchers monitor for treatment-emergent adverse events and measure radiation doses, tracer uptake, tumor-to-background ratios, and lesion detection rates. Participants are followed through the day of their last injection to evaluate safety. The total participation duration depends on individual imaging schedules and treatment plans.
CONDITIONS
Imaging of Solid Tumors Using FAP-2286
M
Maya Aslam
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Thomas Hope
Lead Sponsor
Society of Abdominal Radiology
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | 68Ga-FAP-2286 PET Imaging (Investigational) | FDG PET/CT Imaging (Current Standard) |
|---|---|---|
| What it is | A novel PET radiotracer, Gallium-68 labelled FAP-2286, designed for targeting fibroblast activation protein in solid tumors. Administered intravenously prior to PET imaging. | FDG PET/CT is a widely used diagnostic imaging technique that detects increased glucose metabolism typical of many solid tumors. Imaging is performed after intravenous injection of 18F-FDG, followed by PET/CT scanning. |
| Role in trial | Evaluated as an investigational diagnostic imaging method for identifying and monitoring solid tumors, including metastatic and non-metastatic disease. | Serves as the current-care comparator to assess the clinical performance of the investigational radiotracer in the same population. |
| Primary use | Used in the trial to detect, characterize, and monitor solid tumors, providing information on tumor localization and activity. | Employed clinically to identify the presence and extent of solid tumors, guide treatment planning, and track disease progression or response to therapy. |
| How it is given or performed | Single intravenous infusion of 68Ga-FAP-2286; subsequent PET imaging for 30 to 45 minutes. Radiation dosimetry and uptake values assessed in selected cohorts. | Intravenous injection of 18F-FDG, followed by PET and CT scanning typically lasting less than an hour. Uptake values assessed for tumor detection and monitoring. |
| Evidence status | Undergoing first-in-human clinical evaluation for imaging and dosimetry in solid tumors; result maturity is limited at present. | Supported by extensive published evidence for detecting, staging, and monitoring solid tumors across multiple cancer types; result maturity is high. |
| Important limitations | Limitations include early clinical experience, restricted to trial settings, and limited published efficacy and safety evidence to date. | FDG PET/CT has known limitations, such as false positives in inflammatory or infectious lesions and reduced sensitivity for certain low-FDG-avid tumors. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 3 days
Participants receive an intravenous injection of radiolabeled FAP-2286 followed by PET imaging to detect tumor uptake and metastatic disease.
1 to 3 visits depending on cohort and imaging schedule
Duration - 1 day
Participants are followed through the day of the last injection of radiolabeled FAP-2286 for evaluation of adverse events.
1 visit (in-person)
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Brad Kline, Surekha Yadav, Youngho Seo...
https://pubmed.ncbi.nlm.nih.gov/38697672/Thomas Hope
Lead Sponsor
Society of Abdominal Radiology
Collaborating Sponsor